Real-world patient search trends, site performance benchmarks, and feasibility data — curated for CRO Study Startup Managers, Site Selection Leads, and Biotech Clinical Operations Directors. Delivered every two weeks.
Our readership is drawn from across the CRO and biopharma clinical development ecosystem — decision-makers who need actionable intelligence, not generic oncology news.
Site identification, contract negotiation, and regulatory package preparation. They read us for site performance benchmarks and country-level enrolment velocity data.
Responsible for feasibility surveys, investigator mapping, and site qualification. They use our trend data to prioritise therapeutic area and geography for outreach.
Setting strategy for early Phase I/II programmes. They rely on our intelligence to benchmark competitor enrolment and anticipate patient availability challenges.
Aggregated, anonymised data from our patient navigation platform: which cancer types are generating the highest trial-matching enquiries, and in which US regions — a live signal of where enrolment demand is growing.
One featured site or site network: enrolment velocity, therapeutic area depth, PI track record. A short-form feasibility signal without a full survey process.
FDA guidance updates, amendment trends, and protocol design shifts in oncology — interpreted for their practical impact on study startup timelines and eligibility criteria.
New IND filings, Phase II/III transitions, and discontinued trials in oncology. Competitive landscape snapshots for the therapeutic areas our readers care about most.
Anonymised monthly enrolment velocity data across Phase I, II, and III oncology studies — segmented by tumour type, line of therapy, and biomarker requirement.
One sponsor slot per issue — a site network profile, CRO capability overview, or technology platform introduction. Always transparently marked as sponsored content.
High demand signal: Phase II NSCLC (non-squamous, EGFR-mutant) in the Midwest. Over the past 30 days, KCLG's patient navigation platform registered a 34% increase in trial-matching enquiries for EGFR-mutant, non-squamous NSCLC from Illinois, Ohio, and Indiana — significantly above the 6-month rolling average. Sites in this geography with relevant patient populations may be experiencing under-served demand relative to available trial capacity.
Phase III solid tumour trials averaging 4.2 months from site activation to first patient in. Our anonymised benchmark digest across 22 KCLG-supported or tracked Phase III solid tumour studies shows median time-to-FPI of 4.2 months (IQR: 3.1–5.8). Studies with pre-defined biomarker screening cascades showed a statistically meaningful lag of +1.6 months versus standard eligibility. Consider pre-screening protocol provisions for biomarker-restricted Phase IIIs.
FDA Draft Guidance on Decentralised Trial Elements (September 2026) — key implications for oncology sponsors. The updated draft guidance clarifies remote biospecimen collection requirements and introduces a new framework for hybrid site-DCT models. Oncology trials with mandatory on-site imaging are largely unaffected, but patient-reported outcome collection and symptom monitoring can now be fully remote under the guidance — reducing visit burden without an amendment.
Join 1,400+ CRO and biopharma professionals receiving fortnightly oncology intelligence. No spam. Unsubscribe anytime.
By subscribing you agree to receive the KCLG Oncology Intelligence newsletter. We do not share subscriber data with third parties. See our Privacy Policy.
Reach 1,400+ qualified clinical operations professionals — decision-makers actively sourcing sites, CROs, and technology for live oncology programmes. All sponsorships are clearly labelled as sponsored content.
Beyond the newsletter, KCLG produces bespoke feasibility intelligence reports for sponsors conducting site selection or therapeutic area landscaping. Reports draw on our patient navigation platform data, site network relationships, and clinical operations expertise.
Patient demand analysis by geography and tumour type · Site performance benchmarks for your protocol's eligibility criteria · Competitive trial density mapping (ClinicalTrials.gov + KCLG platform data) · Enrolment velocity projections · Investigator shortlist with PI track records · Regulatory and amendment risk flags for your inclusion/exclusion criteria. Delivered as a PDF briefing document with executive summary. Turnaround: 10–15 business days.